|Datasheet||Specific References||Reviews||Related Products||Protocols|
pMD18-T Simple Vector is a high-efficiency TA cloning vector constructed from pUC18, of which the initial multiple cloning sites (MCS) were destroyed. Thus the cDNA should be amplified by PCR with primers containing a restriction site for subclone. Competent cells appropriate for pUC18 are also appropriated for the Vector, e.g. JM109, DH5α, TOP10. The pMD18-T Simple Vector is 2.6kb in size. Selection of the plasmid in E. coli is conferred by the ampicillin resistance gene. The coding sequence was inserted by TA cloning at site 425.
The coding sequence can be amplified by PCR with M13-47 and RV-M primers.
|Mouse APP / PN2 ORF mammalian expression plasmid, C-GFPSpark tag||MG50402-ACG|
|Mouse APP / PN2 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50402-ACR|
|Mouse APP / PN2 ORF mammalian expression plasmid, C-Flag tag||MG50402-CF|
|Mouse APP / PN2 ORF mammalian expression plasmid, C-His tag||MG50402-CH|
|Mouse APP / PN2 ORF mammalian expression plasmid, C-Myc tag||MG50402-CM|
|Mouse APP / PN2 ORF mammalian expression plasmid, C-HA tag||MG50402-CY|
|Mouse APP / PN2 ORF mammalian expression plasmid, N-Flag tag||MG50402-NF|
|Mouse APP / PN2 ORF mammalian expression plasmid, N-His tag||MG50402-NH|
|Mouse APP / PN2 ORF mammalian expression plasmid, N-Myc tag||MG50402-NM|
|Mouse APP / PN2 ORF mammalian expression plasmid, N-HA tag||MG50402-NY|
|Mouse APP / PN2 natural ORF mammalian expression plasmid||MG50402-UT|
|Learn more about expression Vectors|
Amyloid precursor protein (APP) is a type I transmembrane protein expressed in many tissues and concentrated in the synapses of neurons, and is suggested as a regulator of synapse formation and neural plasticity. APP can be processed by two different proteolytic pathways. In one pathway, APP is cleaved by β- and γ-secretase to produce the amyloid-β-protein (Aβ, Abeta, beta-amyloid) which is the principal component of the amyloid plaques, the major pathological hallmark of Alzheimer’s disease (AD), while in the other pathway, α-secretase is involved in the cleavage of APP whose product exerts antiamyloidogenic effect and prevention of the Aβ peptide formation. The aberrant accumulation of aggregated beta-amyloid peptides (Abeta) as plaques is a hallmark of AD neuropathology and reduction of Abeta has become a leading direction of emerging experimental therapies for the disease. Besides this pathological function of Abeta, recently published data reveal that Abeta also has an essential physiological role in lipid homeostasis. Cholesterol increases Abeta production, and conversely A beta production causes a decrease in cholesterol synthesis. Abeta may be part of a mechanism controlling synaptic activity, acting as a positive regulator presynaptically and a negative regulator postsynaptically. The pathological accumulation of oligomeric Abeta assemblies depresses excitatory transmission at the synaptic level, but also triggers aberrant patterns of neuronal circuit activity and epileptiform discharges at the network level. Abeta-induced dysfunction of inhibitory interneurons likely increases synchrony among excitatory principal cells and contributes to the destabilization of neuronal networks. There is evidence that beta-amyloid can impair blood vessel function. Vascular beta-amyloid deposition, also known as cerebral amyloid angiopathy, is associated with vascular dysfunction in animal and human studies. Alzheimer disease is associated with morphological changes in capillary networks, and soluble beta-amyloid produces abnormal vascular responses to physiological and pharmacological stimuli.